181 related articles for article (PubMed ID: 18398476)
21. Self-assembly of the ionic peptide EAK16: the effect of charge distributions on self-assembly.
Jun S; Hong Y; Imamura H; Ha BY; Bechhoefer J; Chen P
Biophys J; 2004 Aug; 87(2):1249-59. PubMed ID: 15298927
[TBL] [Abstract][Full Text] [Related]
22. Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Indra R; Černá T; Heger Z; Hraběta J; Wilhelm M; Dostálová S; Lengálová A; Martínková M; Adam V; Eckschlager T; Schmeiser HH; Arlt VM; Stiborová M
Toxicology; 2019 May; 419():40-54. PubMed ID: 30914192
[TBL] [Abstract][Full Text] [Related]
23. The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells.
Poljaková J; Eckschlager T; Hrabeta J; Hrebacková J; Smutný S; Frei E; Martínek V; Kizek R; Stiborová M
Biochem Pharmacol; 2009 May; 77(9):1466-79. PubMed ID: 19426684
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxicity of and DNA adduct formation by ellipticine and its micellar form in human leukemia cells in vitro.
Stiborova M; Manhartova Z; Hodek P; Adam V; Kizek R; Eckschlager T; Frei E
Neuro Endocrinol Lett; 2015; 36 Suppl 1():22-8. PubMed ID: 26757112
[TBL] [Abstract][Full Text] [Related]
25. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
[TBL] [Abstract][Full Text] [Related]
26. Fabrication of self-assembling D-form peptide nanofiber scaffold d-EAK16 for rapid hemostasis.
Luo Z; Wang S; Zhang S
Biomaterials; 2011 Mar; 32(8):2013-20. PubMed ID: 21167593
[TBL] [Abstract][Full Text] [Related]
27. The interaction between self - assembling peptides and emodin and the controlled release of emodin from
Wei W; Meng C; Wang Y; Huang Y; Du W; Li H; Liu Y; Song H; Tang F
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3961-3975. PubMed ID: 31588802
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.
Stiborová M; Rupertová M; Frei E
Biochim Biophys Acta; 2011 Jan; 1814(1):175-85. PubMed ID: 20576524
[TBL] [Abstract][Full Text] [Related]
29. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
Fossé P; Charra M; Paoletti C; Saucier JM; René B
Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
[TBL] [Abstract][Full Text] [Related]
30. Design and Characterization of a Multifunctional pH-Triggered Peptide C8 for Selective Anticancer Activity.
Lu S; Bennett WF; Ding Y; Zhang L; Fan HY; Zhao D; Zheng T; Ouyang PK; Li J; Wu Y; Xu W; Chu D; Yuan Y; Heerklotz H; Karttunen M; Chen P
Adv Healthc Mater; 2015 Dec; 4(17):2709-18. PubMed ID: 26474414
[TBL] [Abstract][Full Text] [Related]
31. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
32. New self-assembling polyaspartylhydrazide copolymer micelles for anticancer drug delivery.
Licciardi M; Cavallaro G; Di Stefano M; Pitarresi G; Fiorica C; Giammona G
Int J Pharm; 2010 Aug; 396(1-2):219-28. PubMed ID: 20600731
[TBL] [Abstract][Full Text] [Related]
33. Lysosomal Exocytosis of Olivacine on the Way to Explain Drug Resistance in Cancer Cells.
Wiatrak B; Gębarowski T; Czwojdziński E; Gąsiorowski K; Tylińska B
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682799
[TBL] [Abstract][Full Text] [Related]
34. Interaction of different prototropic species of an anticancer drug ellipticine with HSA and IgG proteins: multispectroscopic and molecular modeling studies.
Thakur R; Das A; Sharma V; Adhikari C; Ghosh KS; Chakraborty A
Phys Chem Chem Phys; 2015 Jul; 17(26):16937-46. PubMed ID: 26060925
[TBL] [Abstract][Full Text] [Related]
35. DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells.
Poljaková J; Frei E; Gomez JE; Aimová D; Eckschlager T; Hrabeta J; Stiborová M
Cancer Lett; 2007 Jul; 252(2):270-9. PubMed ID: 17306925
[TBL] [Abstract][Full Text] [Related]
36. Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Stiborova M; Poljakova J; Eckschlager T; Kizek R; Frei E
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):115-21. PubMed ID: 22837132
[TBL] [Abstract][Full Text] [Related]
37. Hydrophobicity-enhanced ferritin nanoparticles for efficient encapsulation and targeted delivery of hydrophobic drugs to tumor cells.
Incocciati A; Kubeš J; Piacentini R; Cappelletti C; Botta S; Bertuccini L; Šimůnek T; Boffi A; Macone A; Bonamore A
Protein Sci; 2023 Dec; 32(12):e4819. PubMed ID: 37883077
[TBL] [Abstract][Full Text] [Related]
38. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
39. Extending nature's leads: the anticancer agent ellipticine.
Garbett NC; Graves DE
Curr Med Chem Anticancer Agents; 2004 Mar; 4(2):149-72. PubMed ID: 15032720
[TBL] [Abstract][Full Text] [Related]
40. The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.
Stiborová M; Bieler CA; Wiessler M; Frei E
Biochem Pharmacol; 2001 Dec; 62(12):1675-84. PubMed ID: 11755121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
